Goldman Sachs downgraded Ulvac to Sell, with the core concern that strong orders are unlikely to translate into sufficient margin expansion.
AI summary card
Goldman Sachs downgraded Ulvac to Sell, with the core concern that strong orders are unlikely to translate into sufficient margin expansion.
Demand for semiconductor capital spending remains strong, but Ulvac's earnings improvement may be slower than management and market expectations due to capacity bottlenecks, longer lead times, and insufficient pricing power.
- Ulvac was downgraded from Neutral to Sell, with the 12-month target price cut from ¥10,300 to ¥8,200, implying about 18% downside.
- Goldman Sachs expects operating profit forecasts for FY6/27-FY6/29 to be reduced by 18%/15%/12%, respectively, with its FY6/28 forecast more than 20% below Bloomberg consensus.
- The report believes strong industry demand will continue, but margin performance across equipment makers will depend on capacity readiness, product competitiveness, and the ability to pass through higher component costs.
- Ulvac's main semiconductor equipment base is close to its capacity ceiling, and longer lead times may delay revenue recognition; the equipment modularization ratio was about 30% in FY6/26, indicating production reform will still take time to bear fruit.
Report interpretation
Overview
This report focuses on Japan's semiconductor capital equipment sector, especially Ulvac's earnings elasticity in a strong semiconductor capex environment. Goldman Sachs believes that while SPE demand remains solid and customer requests for earlier delivery persist, tightening upstream supply chains and rising component and material prices make equipment makers' pricing strategy, capacity flexibility, and product competitiveness the key drivers of margin divergence. Based on relative coverage comparison, the report downgrades Ulvac from Neutral to Sell.
Core views
The core view is that Ulvac's order growth remains supported, but margin expansion is becoming more difficult. The main reasons include its primary production base nearing its limit, limited room for further capacity increases, longer lead times that may delay revenue recognition, and insufficient market share and competitive positioning outside power semiconductor equipment to support aggressive price hikes. Compared with Lasertec, Ebara, Disco, and Tokyo Electron, which retain Buy ratings, Goldman Sachs believes Ulvac will have greater difficulty achieving both above-industry-average revenue growth and meaningful margin improvement.
Analysis framework
The report uses a combination of top-down industry demand analysis and bottom-up company comparison: first assessing semiconductor manufacturers' capital spending, SPE demand, and supply chain cost trends, then comparing covered companies in terms of capacity, lead times, product competitiveness, and pricing power, and finally cross-checking Ulvac's margin forecasts, valuation multiples, and target price. The target price is based on FY6/28E EBITDA, with reference to the global SPE industry's average EV/EBITDA and Ulvac's relative margin discount.
Methodology notes
Margin Divergence Framework
Against a backdrop of strong demand and rising costs, whether equipment makers can expand margins depends on capacity flexibility, delivery cycles, product competitiveness, and cost pass-through ability.
Target Price Derivation
The report uses FY6/28E EBITDA as the basis, applies the global SPE industry average of 18X EV/EBITDA, and applies a 55% relative discount to Ulvac to reflect its lower margins and uncertainty in its China business.
Earnings Revision
The report lowers operating profit forecasts for FY6/27-FY6/29, mainly due to capacity bottlenecks, longer lead times, rising component costs, and limited pricing power.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- Ulvac (6728.T)Core covered name, downgraded to Sell
- Strengths
- Orders for semiconductor products are in an expansion trend; products related to power semiconductors have high market share; structural reforms have already brought some gross margin improvement.
- Weaknesses
- The main production base is close to its capacity ceiling, with longer lead times; the equipment modularization ratio is still around 30%; pricing power is limited outside power semiconductors; the FY6/28 operating margin forecast remains below the mid-term plan target.
- Comparison
- Compared with Buy-rated names such as Lasertec, Ebara, Disco, and Tokyo Electron, the report believes Ulvac will have greater difficulty achieving above-industry-average sales growth and margin expansion.
- Risks
- The Sell view faces upside risk if structural reforms materialize earlier, pricing succeeds, capacity bottlenecks ease, or China power semiconductor investment recovers.
- Lasertec、Ebara、Disco、Tokyo ElectronPeer comparison references, with Goldman Sachs maintaining Buy ratings
- Strengths
- The report believes these companies are more likely to achieve above-industry-average sales growth and margin expansion in FY26-FY27.
- Weaknesses
- They also face industry pressure from rising upstream component and material prices, as well as customers demanding earlier delivery.
- Comparison
- Relative to Ulvac, these companies are considered to have better product competitiveness, capacity readiness, or pricing ability.
- Risks
- Volatility in industry demand, further increases in supply chain costs, or changes in customer capex timing could affect their comparative advantage.
Key data
- Rating ChangeDowngraded from Neutral to SellBased on relative comparison within coverage.
- New 12-Month Target Price¥8,200Previous target price was ¥10,300.
- Expected Downsideapproximately -18%Calculated relative to the new target price.
- Operating Profit Forecast RevisionsFY6/27 -18%; FY6/28 -15%; FY6/29 -12%Reflects constrained pace of margin improvement.
- FY6/28 Operating Margin Forecast11.8%The report believes achieving the company's mid-term plan target of 15% is not a low hurdle.
- Equipment Modularization Ratioapproximately 30%FY6/26 level, showing production reform is still in progress.
- FY6/28E Valuation ImplicationP/E 17X; P/B 1.5X; EV/EBITDA 8XImplied valuation from the target price.
- Valuation Method Parameters18X global SPE industry average EV/EBITDA, 55% discountThe discount reflects lower margins and uncertainty in the China business.
- FY6/28 Revenue Forecast¥287,600mnSummary financial table forecast.
- FY6/28 Operating Profit Forecast¥33,900mnSummary financial table forecast.
Impact & implications
From an investment perspective, the report does not deny strong semiconductor equipment demand, but instead emphasizes that strong demand will not automatically translate into high earnings elasticity for Ulvac. If capacity bottlenecks and cost pass-through pressure persist, Ulvac's room for valuation expansion relative to peers will be limited, and its share price may struggle to outperform equipment makers with greater capacity flexibility and pricing power.
Risks
- The impact of structural reforms emerges earlier than expected, driving margin improvement.
- Ulvac implements more aggressive product price increases and successfully passes through rising component and material costs.
- Capacity bottlenecks are resolved through productivity gains or utilization of other bases, leading to sales and profits above expectations.
- Investment in Chinese power semiconductors such as SiC recovers, driving order growth for high-margin products.
- Changes in market risk appetite or rising interest rates lead to a preference for low-valuation stocks, driving expansion in Ulvac's valuation multiples.
What to watch
- Capacity utilization, lead time changes, and revenue recognition pace at Ulvac's main production base.
- The pace of equipment modularization and planned production rollout, and whether they can materially improve gross margins.
- Execution strength of the new management team on product price increases and cost pass-through.
- Whether Chinese power semiconductor investment demand, especially for SiC, recovers.
- Whether the FY6/28 operating margin approaches the 15% mid-term plan target.
- Whether Ulvac's EV/EBITDA and P/E multiples relative to SPE peers continue to be constrained by margin expectations.